Versartis Inc., of Menlo Park, Calif., said the safety profile of somavaratan (VRS-317), a long-acting form of recombinant human growth hormone (rhGH), for pediatric growth hormone deficiency, has been maintained with 30 months of treatment in the VISTA study, which followed the phase IIa clinical trial.